Novartis’s operating income grew 123% in Q3 with Entresto
By Son, Hyung Min | translator Alice Kang
24.11.01 05:50:52
가나다라
0
Rises 10% YoY… Entresto tops sales, posting KRW 2.5 trillion
New drugs including Leqvio, Fabhalta were released…immunosuppressant Cosentyx also shows good performance
The Swiss global pharmaceutical giant Novartis' sales increased slightly compared to the previous year. Novartis showed even sales growth in various therapeutic areas, including cardiovascular, anticancer, and immunosuppressive agents.
According to industry sources, Novartis reported a revenue of USD 12.823 billion in Q3 last year, up 10% YoY. The company’s operating income was approximately USD 3.627 billion, a 123% increase YoY.
The largest revenue generator in Q3 was the heart failure drug Entresto. Entresto generated USD 1.865 billion in revenue, up 26% YoY.
Entresto is an angiotensin receptor-neprilysin inhibitor (ARNI) class heart failure drug and is the only
Son, Hyung Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)